Table 8.
History of LC16mO- and LC16m8-based rVVs as vectors for antigen delivery and protein expression (modified and updated from [53])
| Parental vector | rVV nomenclature | Foreign antigen(s) and virus | Insertion site in rVV | Promoter | References |
|---|---|---|---|---|---|
| LC16mO | m0HB9-1 | HBsAg (HBV) | TK | TK | Morita et al. [56] |
| LC16m8 | m8HB20-3 | HBsAg (HBV) | TK | TK | |
| LC16mO | pProHBm0143 | HBsAg (HBV) | TK | 7.5 kDa | Watanabe et al. [27], [57] |
| LC16m8 | pProHBm839 | HBsAg (HBV) | TK | 7.5 kDa | |
| LC16mO | m0-proenv | Env (HTLV-1) | HA | 7.5 kDa | Shida et al. [58] |
| LC16mO | m0J6 | PreM & E glycoproteins (JEV) | TK | 7.5 kDa | Yasuda et al. [59] |
| LC16mO | m0-HA/ATI | Env (BLV) | HA | ATI | Ohishi et al. [60] |
| m0-HA/7.5kD | Env (BLV) | HA | 7.5 kDa | ||
| LC16mO | mp7.5/RVV | Hemagglutinin (RPV) | HA | 7.5 kDa | Asano et al. [61] |
| LC16mO | p7.5/RVV | Hemagglutinin (RPV) | HA | 7.5 kDa | Yamanouchi et al. [62] |
| LC16mO | VgB, VgC, VgD | gB, gC, gD (CHV) | TK | 7.5 kDa | Xuan et al. [63] |
| LC16mO | rRV | Hemagglutinin (RPV) | HA | 7.5 kDa | Ohishi et al. [64] |
| LC16mO | m0TDH/HisX1, m0TDH/HisC2, m0TDF1 | Hemagglutinin (MV) F protein (MV) | HA | pSFJ1-10 and pSFJ2-16 (ATI + tandem repeats of p7.5 kDa) | Kidokoro et al. [55] |
| LC16m8 | SARS CoV-S rVV | Spike protein (SARS coronavirus) | HA | pSFJ1-10 | Kitabatake et al. [54] |
ATI = A-type inclusion body; BLV = bovine leukemia virus; CHV = canine herpesvirus; HA = hemagglutinin; HBV = hepatitis B virus; HTLV-1 = human T-cell leukemia virus type 1; JEV = Japanese encephalitis virus; MV = measles virus; RPV = rinderpest virus; SARS = severe acute respiratory syndrome; TK = thymidine kinase.